Risks

CGM reimbursement pressure and payer utilization management could slow adoption and pricing versus diversified medtech peers, but Dexcom’s installed base and clinical evidence partially cushion demand.

Abbott’s FreeStyle Libre scale and lower-cost positioning may intensify share competition in type 2 and international channels, pressuring Dexcom’s growth mix more than premium device peers.

Supply-chain and manufacturing execution risk remains material in a high-volume sensor model, yet Dexcom’s operating scale and improving logistics reduce disruption risk relative to smaller device competitors.

Long cash conversion cycle and elevated inventory days can constrain working-capital flexibility if demand normalizes unevenly, although the balance sheet remains stronger than highly levered medtech peers.

Opportunities

Broader CGM penetration in type 2 diabetes and non-insulin users can expand the addressable market, and Dexcom is better positioned than most peers to capture that secular shift.

International reimbursement expansion and channel rollout could lift growth over several years, with Dexcom’s brand and clinical positioning giving it an advantage over smaller CGM entrants.

Integration of CGM into connected care and automated insulin delivery ecosystems can deepen switching costs, and Dexcom’s ecosystem breadth compares favorably with single-product competitors.

Premium sensor accuracy and real-time data features support pricing resilience versus lower-cost rivals, helping Dexcom defend margins better than commoditized glucose-monitoring alternatives.

Overall Score

Dexcom’s forward positioning is strong because secular CGM adoption, international expansion, and ecosystem integration outweigh reimbursement and Libre-driven competition, though working-capital and execution risks remain relevant.